| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | B Douglas Smith | |
| Richard J Jones | |||
| William Matsui | |||
| Carol Ann Huff | |||
| P2860 | cites work | Cancerous stem cells can arise from pediatric brain tumors | Q24569653 |
| Characterization of clonogenic multiple myeloma cells | Q24610291 | ||
| Prospective identification of tumorigenic breast cancer cells | Q24683474 | ||
| Stem cells, cancer, and cancer stem cells | Q27860878 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell | Q27861001 | ||
| Identification of a cancer stem cell in human brain tumors | Q28131688 | ||
| A cell initiating human acute myeloid leukaemia after transplantation into SCID mice | Q28131777 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 | ||
| Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control | Q30822410 | ||
| Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer | Q33208591 | ||
| Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group | Q33348775 | ||
| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 | ||
| Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders | Q34430888 | ||
| Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? | Q34542144 | ||
| Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate | Q34550827 | ||
| Chemotherapy of prostate cancer: present and future | Q35131057 | ||
| Goals and objectives in the management of metastatic breast cancer | Q35600946 | ||
| Indolent lymphoma: the pathologist's viewpoint. | Q35609276 | ||
| Cancer stem cells: are we missing the target? | Q35752241 | ||
| Clonal origin of chronic myelocytic leukemia in man | Q36455132 | ||
| Chronic myelogenous leukemia. Clinical practice guidelines in oncology | Q37602107 | ||
| Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors | Q40393545 | ||
| Dynamics of chronic myeloid leukaemia. | Q40403398 | ||
| Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor | Q40627595 | ||
| The specific enhancement of interferon alpha induced growth inhibition by BCR/ABL only occurs in multipotent cells | Q40741749 | ||
| Natural history of and therapy for the indolent non-Hodgkin's lymphomas. | Q40766999 | ||
| Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials | Q43606238 | ||
| Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro | Q43833442 | ||
| Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation | Q43977712 | ||
| Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. | Q44356040 | ||
| Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival | Q44407580 | ||
| Discontinuation of imatinib therapy after achieving a molecular response | Q45065538 | ||
| Cancer biology: summing up cancer stem cells. | Q46575709 | ||
| Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia. | Q46621816 | ||
| BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. | Q51141709 | ||
| Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. | Q53389384 | ||
| CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications | Q56991197 | ||
| Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients | Q61914822 | ||
| The natural history of initially untreated low-grade non-Hodgkin's lymphomas | Q70817025 | ||
| Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia | Q73963311 | ||
| In AML t(8;21) colony growth of both leukemic and residual normal progenitors is restricted to the CD34+, lineage-negative fraction | Q77585002 | ||
| Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR- | Q77620589 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 431-434 | |
| P577 | publication date | 2005-09-08 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | The paradox of response and survival in cancer therapeutics | |
| P478 | volume | 107 |
| Q38836045 | (18)F-fluoromisonidazole PET reveals spatial and temporal heterogeneity of hypoxia in mouse models of human non-small-cell lung cancer |
| Q35885317 | A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia |
| Q37681007 | A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms |
| Q37729195 | Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. |
| Q37325012 | Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors |
| Q85246435 | All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells |
| Q53345637 | Apoptosis: the suicide solution in cancer treatment and chemoprevention. |
| Q39724856 | Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells |
| Q39922525 | CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers |
| Q35765724 | Cancer Stem Cells: From Bench to Bedside |
| Q37010433 | Cancer induction by restriction of oncogene expression to the stem cell compartment |
| Q37079713 | Cancer stem cells--old concepts, new insights. |
| Q34729707 | Cancer stem cells-clinical relevance |
| Q37398584 | Cancer stem cells: relevance to SCT |
| Q27008959 | Cancer stem cells: relevance to clinical transplantation |
| Q39762419 | Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells |
| Q44955932 | Canine indolent and aggressive lymphoma: clinical spectrum with histologic correlation. |
| Q50994157 | Chemotherapy-Induced Ca2+ Release Stimulates Breast Cancer Stem Cell Enrichment. |
| Q37467572 | Cisplatin and TRAIL enhance breast cancer stem cell death |
| Q38026464 | Clinical implication of targeting of cancer stem cells |
| Q24644883 | Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance |
| Q35971159 | Concise review: Emerging concepts in clinical targeting of cancer stem cells |
| Q47670493 | Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. |
| Q42594318 | Drug resistance in cancer: molecular evolution and compensatory proliferation |
| Q89777306 | EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT |
| Q36352817 | EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model |
| Q41859828 | Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy |
| Q37220185 | Epithelial stem cells and malignancy. |
| Q93079651 | Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture |
| Q37425433 | FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies |
| Q34978457 | From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors |
| Q42600565 | Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells |
| Q36309873 | Heat stress induces epithelial plasticity and cell migration independent of heat shock factor 1. |
| Q48102797 | High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. |
| Q37126963 | Hypoxia in microscopic tumors. |
| Q42181722 | Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab |
| Q37148370 | Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component |
| Q37773301 | Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant |
| Q92087958 | Magnetic resonance imaging features of tumor and lymph node to predict clinical outcome in node-positive cervical cancer: a retrospective analysis |
| Q27333860 | Modeling evolutionary dynamics of epigenetic mutations in hierarchically organized tumors |
| Q37698645 | Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis |
| Q30490247 | Pancreatic cancer. |
| Q34037747 | Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century |
| Q37181702 | Pin1-Nanog expression in human glioma is correlated with advanced tumor progression |
| Q28741720 | Post-genomic clinical trials: the perspective of ACGT |
| Q38089206 | Preclinical development of cancer stem cell drugs |
| Q81100907 | Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial |
| Q44422836 | Risk factors for suicide among older adults with cancer |
| Q36605667 | Somatic stem cells and the origin of cancer |
| Q53264975 | Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. |
| Q84863800 | Stem cells |
| Q37505384 | Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas. |
| Q33925257 | Targeting Hedgehog--a cancer stem cell pathway |
| Q57139325 | Targeting breast cancer stem cells |
| Q34505105 | Targeting breast cancer stem cells |
| Q34218232 | Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis |
| Q37980960 | The developing cancer stem-cell model: clinical challenges and opportunities |
| Q37403285 | Therapeutic implications of the cancer stem cell hypothesis. |
| Q26772032 | Tissue Regeneration in the Chronically Inflamed Tumor Environment: Implications for Cell Fusion Driven Tumor Progression and Therapy Resistant Tumor Hybrid Cells |
| Q36759364 | Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer |
| Q37606286 | Tumour-initiating cells: challenges and opportunities for anticancer drug discovery |
| Q28481716 | Yeasts acquire resistance secondary to antifungal drug treatment by adaptive mutagenesis |
| Q33576814 | microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers |
Search more.